Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.38 |
| ▸ | GRM4 | Q14833 | 12/20 | 0.38 |
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.37 |
| ▸ | PIM1 | P11309 | 1/20 | 0.36 |
| ▸ | XDH | P47989 | 1/20 | 0.36 |
| ▸ | DHFR | P00374 | 1/20 | 0.36 |
| ▸ | DCPS | Q96C86 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4554263 | 0.80 | HDAC6 (0.47) | GRM4LRRK2 | |
| SCHEMBL14167604 | 0.79 | PIM1 (0.39) | GRM4LRRK2PIM1XDHDHFR | |
| SCHEMBL8277614 | 0.78 | GRM4 (0.42) | IRAK4GRM4LRRK2DHFRDCPS | |
| SCHEMBL15716837 | 0.78 | CCNA2 (0.43) | IRAK4GRM4LRRK2PIM1XDH | |
| SCHEMBL30537234 | 0.77 | XDH (0.50) | IRAK4GRM4XDH | |
| SCHEMBL20502377 | 0.77 | XDH (0.50) | IRAK4GRM4XDH | |
| SCHEMBL30939176 | 0.76 | LOXL2 (0.52) | IRAK4GRM4DHFRDCPS | |
| SCHEMBL29954310 | 0.76 | SLC2A1 (0.45) | PIM1DHFRDCPS | |
| SCHEMBL4937792 | 0.76 | XDH (0.41) | IRAK4LRRK2PIM1XDHDHFR | |
| SCHEMBL4935143 | 0.76 | LOXL2 (0.52) | IRAK4GRM4DHFRDCPS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9663533-B2 | Thieno[3,2-C]pyridin-4(5H)-ones as BET inhibitors | GLAXOSMITHKLINE LLC (US) | 2017-05-30 | — | — | US | disclosed |
| EP-2920183-B1 | THIENO[3,2-C]PYRIDIN-4(5H)-ONES AS BET INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2017-03-08 | — | — | EP | disclosed |
| US-20160297832-A1 | THIENO[3,2-C]PYRIDIN-4(5H)-ONES AS BET INHIBITORS | GLAXOSMITHKLINE LLC | 2016-10-13 | — | — | US | disclosed |
| EP-2920183-A1 | THIENO[3,2-C]PYRIDIN-4(5H)-ONES AS BET INHIBITORS | Glaxosmithkline LLC (US) | 2015-09-23 | — | — | EP | disclosed |
| WO-2014078257-A1 | THIENO[3,2-C]PYRIDIN-4(5H)-ONES AS BET INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2014-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160297832-A1 | THIENO[3,2-C]PYRIDIN-4(5H)-ONES AS BET INHIBITORS | BRD4, BET1, BRD3 | IRAK4 1067/4885GRM4 3052/4885LRRK2 890/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.